# BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC

> **NCT03791398** · PHASE1,PHASE2 · TERMINATED · sponsor: **Brown University** · enrollment: 13 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Dose level 1 ONC201 625mg
- **DRUG:** Dose level 2 ONC201 500mg
- **DRUG:** Dose level 3 ONC201 375mg

## Key facts

- **NCT ID:** NCT03791398
- **Lead sponsor:** Brown University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-15
- **Primary completion:** 2021-06-16
- **Final completion:** 2021-08-05
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2023-02-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03791398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03791398, "BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03791398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*